Phase II Trial of Regorafenib and Oral Methotrexate in Previously Treated Advanced KRAS-Mutant NSCLC by Jacqueline V. Aredo, MD, MS, Heather A. Wakelee, MD, Kavitha J. Ramchandran, MD, Joel W. Neal, MD, PhD, Maximilian Diehn, MD, PhD, Angela Bik-Yu Hui, PhD, Ameen Salahudeen, MD, PhD, Bernice Kwong, MD, Gerald J. Berry, MD, H. Henry Guo, MD, PhD, Kristen Cunanan, PhD, Shireen Vali, PhD, Danny Pancirer, BA, Vivian Tsang, MSN, Grace Hwang, MS, Monica Loza, BA, Brittany Johnson, BA, Isabelle Blanchard, BS, Sukhmani K. Padda, MD

Get full text